Clinical advancements in the field of urology are featured in the news media every day. This section provides patients and physicians with the most up-to-date information on recent urologic advancements around the world.
* Please Note - TUCC does not necessarily advocate any of the treatment methods listed in the articles below. This news feed is provided as a resource for those interested in the latest urologic research occurring around the world.
Drugs designed to lower cholesterol may turn out to be an effective weapon against prostate cancer, research has shown.
These data demonstrate the development and clinical utility of a novel liposomal formulation for the treatment of prostate cancer.
Understanding the complexity of cancer is a major goal of the scientific community, and for kidney cancer researchers this goal just got closer.
Although the association between higher hospital volume and improved outcomes has been well-documented in surgery, there is little data about whether this effect exists for radiation-treated patients. This study investigated whether treatment at a radiation facility that treats a high volume of prostate cancer patients is associated with improved survival for men with high-risk prostate cancer.
As men age, they lose testosterone — which some say affects their sense of well-being and sexual function. But for healthy older men, using supplemental testosterone as a remedy has been controversial. Past studies of the supplement's use have been relatively small, and the evidence about benefits and risks has been mixed.
Now a well-designed study published online Wednesday, in the New England Journal of Medicine, confirms certain benefits in sexual function and mood for some men 65 and over, at least in the first year. Though the gains were modest, and some tended to wane in the latter months of treatment, researchers say the findings are encouraging, and merit further research.
Investigators have created a DNA damage and repair (DDR) pathway profiling method that may be used in the management of patients with high-risk prostate cancer, according to an article published in JAMA Oncology.
The objective of the TERRAIN study was to compare the efficacy and safety of enzalutamide with bicalutamide in patients with metastatic castration-resistant prostate cancer.
When to stop watchful waiting and begin definitive treatment of African American patients explored in The Journal of Urology
A new study published in The Journal of Urology® revealed that African American men with Gleason score 3+3=6 prostate cancer (PCa) produce less prostate specific antigen (PSA) and have significantly lower PSA density (PSAD) than Caucasian men. These findings could have important implications when selecting patients for inclusion in active PCa surveillance programs.
Patients with metabolic syndrome (MetS) are at elevated risk of bladder cancer, according to a new study.
In a hospital-based case-control study, researchers led by Maurizio Montella, MD, of Istituto Tumori “Fondazione Pascale IRCCS,” Naples, Italy, compared 690 patients with incident urothelial carcinoma of the bladder (UCB) and 665 cancer-free matched control patients.
Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibition with olaparib.
TUCC is contracted with all major insurance companies. We look forward to providing you with clinically advanced, compassionate urologic care.